New hope for tough anemia: daratumumab trial launches

NCT ID NCT07287228

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests daratumumab, a drug that targets certain immune cells, in 37 people with aplastic anemia that hasn't improved with standard treatments. The first part checks safety and the right dose, and the second part looks at whether it can improve blood cell counts. The goal is to see if this drug can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab
What this could lead to: If successful, this could provide a new treatment option for patients with aplastic anemia that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply broadly. Daratumumab can cause infusion reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA REFRACTORY RELAPSE

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical School

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.